Flatiron Health
Flatiron Health’s mission is to improve and extend lives by learning from the experience of every person with cancer.www.flatiron.com
20
MENTIONS
18
EPISODES
14
PODCASTS
Search complete. 20 mentions across 18 episodes found for "Flatiron Health".
Nov 16, 2026
Big Changes Are Underway for Medicare | CMS Chief AI & Technology Officer, Jacob Schiff
S
1:33Steve KrausHOST
Before CMS, he actually himself was a founder, led a company called Anomaly, which is a venture-backed startup using AI to streamline healthcare payments.
S
1:42Steve KrausHOST
Before that, he was at Flatiron Health, one of the leading healthcare venture success stories, and then Google, not a small company itself.
S
1:49Steve KrausHOST
So, Jacob, thanks for joining the Heart of Healthcare.
S
1:52Steve KrausHOST
It's great to be here.
Targeted Therapy in Early-Stage Resectable NSCLC: Updates from WCLC 2026
E
9:41Eric SinghiGUEST
I was really excited to be able to present this at WCLC.
E
9:44Eric SinghiGUEST
What Adora told us, what the eight-year update told us was, you know, what can three years of ulcerative mortonib do? What can it accomplish in a clinical trial setting? But we wanted to figure out from a practical standpoint, are patients actually staying on therapy for those three years in the real world? And so what we did was we used the Flatiron Health database, US-centric, of course, right, to look at just over 800 patients with resected EGFR mutant non-small cell lung cancer who were treated with adjuvant osomertinib.
E
10:09Eric SinghiGUEST
And we found some pretty striking results.
E
10:11Eric SinghiGUEST
So at year one, approximately 75% of patients were still on adjuvant osomertinib.
Sagar Lonial, MD, FACP - Preserving Efficacy in R/R Myeloma: Emerging CELMoD Strategies and Implications for Sequential Care
S
2:49Sagar LonialGUEST
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
S
2:57Sagar LonialGUEST
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
S
3:14Sagar LonialGUEST
And while we certainly have great therapeutic options, and we're gonna talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
S
3:25Sagar LonialGUEST
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar Lonial, MD, FACP - Preserving Efficacy in R/R Myeloma: Emerging CELMoD Strategies and Implications for Sequential Care
S
2:49Sagar LonialHOST
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
S
2:57Sagar LonialHOST
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
S
3:14Sagar LonialHOST
And while we certainly have great therapeutic options, and we're going to talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
S
3:25Sagar LonialHOST
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar Lonial, MD, FACP - Preserving Efficacy in R/R Myeloma: Emerging CELMoD Strategies and Implications for Sequential Care
S
2:49Sagar LonialGUEST
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
S
2:57Sagar LonialGUEST
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
S
3:14Sagar LonialGUEST
And while we certainly have great therapeutic options, and we're gonna talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
S
3:25Sagar LonialGUEST
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar Lonial, MD, FACP - Preserving Efficacy in R/R Myeloma: Emerging CELMoD Strategies and Implications for Sequential Care
S
2:49Sagar LonialHOST
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
S
2:57Sagar LonialHOST
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
S
3:14Sagar LonialHOST
And while we certainly have great therapeutic options, and we're going to talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
S
3:25Sagar LonialHOST
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Proximal Ventures raises debut fund to back startups bringing AI to drug development; plus, PSI is trying to make a business out of AI-driven scientific discovery
J
3:11Jason RowleyNARRATOR
which uses AI to analyze biological and medical data to better understand chronic diseases and identify potential treatments.
J
3:20Jason RowleyNARRATOR
Before spending two years as a principal at SignalFire, Rauf led business development at clinical trial recruitment startup Iterative Health and previously oversaw partnerships at Flatiron Health, an oncology data company acquired by Roche, for $1.9 billion back in 2018.
J
3:39Jason RowleyNARRATOR
Rauf said, if you're building a company that's selling into the life sciences, one of the hardest things to do is starting that initial commercial flywheel.
J
3:49Jason RowleyNARRATOR
His sales chops, deep understanding of the healthcare ecosystem, and extensive industry relationships gave Limited Partners, the investors in VC Funds, the confidence that he could spot strong startups and help them land customers.
J
4:04Jason RowleyNARRATOR
Proximal's backers include VC firms SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Dimension Capital co-founders Nan Li and Zivane Darr.
J
4:18Jason RowleyNARRATOR
Anne Abernathy, co-founder of Highlander Health and former principal deputy commissioner of the FDA, is also an investor.
J
4:25Jason RowleyNARRATOR
She first met Raouf when they worked together at Flatiron Health, where she served as chief medical officer.
J
4:32Jason RowleyNARRATOR
She told TechCrunch that his ability to build relationships and spot industry bottlenecks made a lasting impression.
Getting Pharma AI Agents to the Right Answer by Fixing the Data and Semantic Layers - with Richard Knoche of Flatiron Health
S
0:12speaker_0NARRATOR
Welcome everyone to the Emoj AI in Business podcast.
S
0:15speaker_0NARRATOR
Today's guest is Richard Kanaki, head of data science and AI at Flatiron Health.
S
0:20speaker_0NARRATOR
Flatiron Health develops technology and data solutions that help oncology teams generate and apply real-world evidence to improve cancer care and research.
S
0:28speaker_0NARRATOR
Its platform connects clinical expertise with structured data and AI-enabled insights to support treatment, regulatory, and scientific decision-making.
S
0:36speaker_0NARRATOR
In this episode, Richard explains why AI agents in pharma are only as reliable as the data foundation and semantic layer beneath them.
Sagar Lonial, MD, FACP / Krina Patel, MD, MSc - Re-Booting Modern Treatment for Relapsed/Refractory Myeloma: Innovative Therapeutics and Implications for Patient Care
S
2:08Sagar LonialHOST
And what we see with the real-world patterns is that there remain ongoing challenges in relapsed and refractory myeloma.
S
2:15Sagar LonialHOST
Data from the Preamble study, the ConnectMM study, and the Flatiron Health retrospective data analyses demonstrating that about 70% of patients developed triple-class refractory and yet continued to reuse prior drug classes.
S
2:31Sagar LonialHOST
What this means is that many patients cycled through previous mechanisms without necessarily getting the benefit of new therapeutic approaches.
S
2:39Sagar LonialHOST
And these are, in fact, the top four challenges for patients and myeloma docs in the community.
Sagar Lonial, MD, FACP / Krina Patel, MD, MSc - Re-Booting Modern Treatment for Relapsed/Refractory Myeloma: Innovative Therapeutics and Implications for Patient Care
S
2:08Sagar LonialHOST
And what we see with the real world patterns is that there remain ongoing challenges in relapsed and refractory myeloma.
S
2:15Sagar LonialHOST
Data from the Preamble study, the ConnectMM study, and the Flatiron Health retrospective data analyses demonstrating that about 70% of patients developed triple-class refractory and yet continued to reuse prior drug classes.
S
2:31Sagar LonialHOST
What this means is that many patients cycled through previous mechanisms without necessarily getting the benefit of new therapeutic approaches.
S
2:39Sagar LonialHOST
And these are, in fact, the top four challenges for patients and myeloma docs in the community.
8 more episodes mention Flatiron Health.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.